On 25th June 2010, Dr. Peter Small, Senior Program Officer of the Bill & Melinda Gates Foundation visited CapitalBio Corp accompanied by the Foundation’s senior Beijing representative, Dr. Daniel Chin.
The director of CapitalBio and the NERCBBT, Dr. Jing Cheng introduced the R&D and products of the company. Cheng explained to the visitors the utility of the CapitalBio tuberculosis drug resistance detection array kit and mycobacteria identification kit and provided details about the mission of CapitalBio to develop relevant clinical products to help control of the tuberculosis epidemic in China. Dr. Cheng also noted the use of the CapitalBio qRT-PCR kit for initial patient screening for TB and NTM infections and the benefits of the use of its deafness gene mutation detection kit in conjunction with mycobacteria array kits to avoid potential antibiotic induced damage during treatment of TB patients.
Dr. Peter Small and Dr. Daniel Chin congratulated CapitalBio on its broad achievements and noted particularly the innovative contribution to the national health and safety system of China with the company’s various TB related test kits.
About The Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation was established in January 2000. It is the world largest non-profit foundation and is dedicated to bringing innovations in health and learning to the global community. On 1st April 2009, the Bill & Melinda Gates Foundation jointed with the Chinese Ministry of Health to form an innovative partnership to fight the serious tuberculosis epidemic in China. The initiative is led by the Chinese Ministry of Health and is supported by a grant of US$33 million over five years from the Gates Foundation. The goal of the partnership is to improve detection and treatment of the estimated 1.5 million TB cases that occur each year in China, drawing on the latest innovations in TB control. Funding from the Foundation will help China introduce new TB diagnostic tests, drug regimens, patient monitoring strategies, and health delivery approaches that could significantly improve the effectiveness of TB diagnosis and treatment across the country.
